icon-    folder.gif   Conference Reports for NATAP  
 
  AIDS 2022
July 29 - Aug 2
24th Intl AIDS Conference
Back cgrey_arrow_rt.gif
 
 
 
Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies
 
 
  AIDS 2022 July 29-Aug 1 Montreal
 
Sharon Walmsley,1 Don E. Smith,2 Miguel Górgolas,3 Pedro E. Cahn,4 Thomas Lutz,5 Karine Lacombe,6 Princy N. Kumar,7 Brian Wynne,8 Richard Grove,9
Gilda Bontempo,8 Riya Moodley,10 Frank Spinelli,8 Bryn Jones,10 Chinyere Okoli,10 Mounir Ait-Khaled10
1University Health Network, Toronto, ON, Canada; 2Albion Centre, Sydney, Australia; 3Fundación Jimenez Díaz, Universidad Autónoma de Madrid, Madrid, Spain; 4Fundación Huesped, Buenos Aires,
Argentina; 5Infektiologikum, Frankfurt, Germany; 6Hopital Saint-Antoine, Paris, France; 7Georgetown University Medical Center, Washington, DC, USA; 8ViiV Healthcare, Durham, NC, USA;
9GSK, Brentford, UK; 10ViiV Healthcare, Brentford

0804221copy

0804222copy

0804223copy

0804224copy

0804225copy

0804226copy

0804227copy

0804228copy

0804229copy

08042210copy